SCHEMBL1573945

SCHEMBL1573945

CN(C)C1CN(C(=O)Nc2ccc(Cl)cc2)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54
TAS1R2 Q8TE23 1/20 0.54
ALOX5 P09917 1/20 0.52
LMNA P02545 4/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
TDP1 Q9NUW8 1/20 0.51
MAPT P10636 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
TP53 P04637 2/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
TSHR P16473 1/20 0.50
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
CA12 O43570 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1574694 0.86 RAB9A (0.58) TAS1R3TAS1R1TAS1R2LMNARAB9A
SCHEMBL1574392 0.85 NPC1 (0.58) RAB9ANPC1MAPTSMN1; SMN2TP53
SCHEMBL24381790 0.85 KDM4E (0.67) LMNARAB9ANPC1TDP1MAPT
SCHEMBL1575309 0.85 NPSR1 (0.58) MAPTSMN1; SMN2GAAMEN1KMT2A
SCHEMBL1574934 0.85 KMT2A (0.56) RAB9ANPC1MAPTSMN1; SMN2KDM4E
SCHEMBL1574458 0.84 TAS1R3 (0.50) TAS1R3TAS1R1TAS1R2ALOX5LMNA
SCHEMBL1574949 0.84 ALOX5 (0.52) TAS1R3TAS1R1TAS1R2ALOX5LMNA
SCHEMBL1574853 0.84 MAPT (0.54) TAS1R3TAS1R1TAS1R2ALOX5LMNA
SCHEMBL1574407 0.83 ALDH1A1 (0.62) RAB9ANPC1MAPTSMN1; SMN2TSHR
SCHEMBL1574956 0.82 MAPT (0.66) TAS1R3TAS1R1TAS1R2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB TAS1R3 4140/4885TAS1R1 4237/4885TAS1R2 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.